Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Oncopeptides AB ( (SE:ONCO) ) is now available.
Oncopeptides AB reported a significant 161% increase in net sales in Q1 2025 compared to the previous year, driven by its expanded commercial footprint in Europe and strategic initiatives. The company secured its first orders in Italy following a positive reimbursement decision and is progressing with partnership negotiations in Japan. Additionally, the FDA lifted the clinical hold on its next-generation drug OPD5, opening new opportunities for market expansion in the U.S. These developments underscore Oncopeptides’ commitment to enhancing its market position and advancing its innovative pipeline.
More about Oncopeptides AB
Oncopeptides AB is a biotech company focused on developing innovative treatments for cancer, particularly in the field of peptide-drug conjugates. The company has a growing presence in key European markets such as Germany, Spain, and Italy, and is working on expanding its market reach, including potential partnerships in Japan.
Average Trading Volume: 898,693
Current Market Cap: SEK414.1M
Learn more about ONCO stock on TipRanks’ Stock Analysis page.